Optimum Misoprostol Dose Prior to Office Hysteroscopy

Cairo University (CU)

Status and phase: Completed; Phase 3

Conditions: Infertility; Recurrent Abortion; Abnormal Uterine and Vaginal Bleeding, Unspecified

Treatments: Drug: Misoprostol

Study type: Interventional

Funder types: Other

Identifiers

NCT01612065

2752012

Details and patient eligibility

About

Misoprostol is an effective agent for cervical priming before office hysteroscopy, vaginal route is the best, optimum dose not yet known.

Full description

The investigators will compare between 2 different doses of vaginal misoprostol, group (1) 200 ug, group (2) 400 ug, 3hours prior to office hysteroscopy , Infertile patient, patients with abnormal bleeding and patient with recurrent abortion Outcome measure: pain score, easiness of the procedure, procedure time, complications

Enrollment: 132 patients

Sex: Female

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Female patient pre- or postmenopausal undergo office hysteroscopy.
• Age: from 20 to 60.
• BMI between 18 and 30.

Exclusion criteria

• PID or
• Heavy uterine bleeding
• Cervical malignancy.
• Symptoms suggestive of endometriosis .
• Any cervical abnormality such as pinhole cervix that would obviate passage of a catheter through the cervix.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

132 participants in 2 patient groups

Misoprostol vaginally, 200 ug

Active Comparator group

Description:

200 ug misoprostol in the posterior vaginal fornix

Treatment:

Drug: Misoprostol

Drug: Misoprostol

Misoprostol vaginally, 400ug

Active Comparator group

Description:

Misoprostol in the posterior vaginal fornix

Treatment:

Drug: Misoprostol

Drug: Misoprostol